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For Korean dialysis patients, chronic kidney disease–mineral bone disorder is a serious
burden because of cardiovascular calciﬁcation and mortality. However, recent epide-
miologic data have demonstrated that many patients undergoing maintenance
hemodialysis are out of the target ranges of serum calcium, phosphorus, and intact
parathyroid hormone. Thus, we felt the necessity for the development of practical
recommendations to treat abnormal serum phosphorus, calcium, and iPTH in dialysis
patients. In this paper, we brieﬂy comment on the measurement of serum calcium,
phosphorus, iPTH, dialysate calcium concentration, dietary phosphorus restriction, use
of phosphate binders, and medical and surgical options to correct secondary hyperpar-
athyroidism. In particular, for the optimal management of secondary hyperparathyr-
oidism, we suggest a simpliﬁed medication adjustment according to certain ranges of
serum phosphorus and calcium. Large-scale, well-designed clinical studies are required
to support our strategies to control chronic kidney disease–mineral bone disorder in
this country. Based on such data, our practice guidelines could be established and
better long-term outcomes should be anticipated in our dialysis patients.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic kidney disease–mineral bone disorder (CKD-MBD) is a
common complication occurring in CKD patients. In addition to
hypercalcemia and hyperphosphatemia, CKD-MBD can cause
vascular calciﬁcation and cardiovascular diseases (CVD), and these
conditions are closely associated with an increased mortality rate.
Recently, these associations have been demonstrated, even in
early-stage CKD patients [1–3]. According to the end-stage renal
disease registry of the Korean Society of Nephrology, there were15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
y, Department of Internal Me
.48,531 hemodialysis (HD) and 7,552 peritoneal dialysis (PD)
patients in Korea in 2012, and CVD was the most common cause
of death in dialysis patients [4].
We previously analyzed the serum levels of calcium (Ca),
phosphorus (P), and intact parathyroid hormone (iPTH) from a
total of 1,018 patients undergoing chronic HD in 17 centers
throughout Korea [5]. The mean serum levels of Ca, P, and
the Ca-P product were 9.1 mg/dL, 5.3 mg/dL and 48.0 mg2/dL2,
respectively. When classiﬁed by the recommended range
according to the Kidney Disease Outcome Quality Initiativehrology. Published by Elsevier. This is an open access article under the
dicine, Korea University College of Medicine, Guro 2-dong,
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trolled hyperphosphatemia 4 5.5 mg/dL. In addition, 270
patients (26.5%) had iPTH 4 300 pg/mL whereas 435 patients
(42.7%) showed iPTH o 150 pg/mL. This study demonstrated
the current status of CKD-MBD in our HD patients, revealing
that a relatively modest proportion of patients had values
outside of the target range [5]. Those patients who were out of
the target range might be associated with poor prognosis,
including mortality secondary to CVD. Therefore, successful
implementation of treatment guidelines is required with
respect to CKD-MBD.
To improve the quality of care in CKD-MBD, global and
regional guidelines were established and suggested target
ranges and treatment protocols. In Korea, the KDOQI and the
Kidney Disease: Improving Global Outcomes (KDIGO) guide-
lines are well known and commonly used [6,7]. In both global
guidelines, however, the level of recommendations is low
because of scarcity of randomized controlled clinical trials.
On regional bases, guidelines were published from Japan
(Japanese Society for Dialysis Therapy, JSDT), Australia (the
Caring for Australians with Renal Impairment, CARI), Great
Britain (United Kingdom Renal Association, UKRA), and Europe
(European Renal Best Practice, ERBP) [8–11]. The target levels
of Ca, P, and iPTH presented in the aforementioned guidelines
are summarized in Table 1.
The target ranges in these guidelines are not consistent, and
we may have to choose one of them because we have no well
performed epidemiological data showing associations
between serum mineral values and patient outcomes in our
dialysis population. Furthermore, in Korea, it is practically
difﬁcult to just adapt foreign guidelines because our treatment
strategies are guided by the National Health Insurance Service
(NHIS) standards. With regard to this point, we reviewed the
CKD-MBD guidelines from different countries and suggest that
our treatment recommendations to be applied in real practices
of CKD-MBD in Korea.Table 2. Recommended measurement frequency and ranges of
serum calcium, phosphorus, and parathyroid hormone in chronic
kidney disease stage 5D
Serum parameters Measurement
frequency
Recommended
range
Calcium Once per mo 8.4–9.6 mg/dL
Phosphorus Once per mo 2.4–5.0 mg/dL
Parathyroid hormone Once every 3 mo 100–300 pg/mLMeasurement of serum Ca, P, and iPTH
In dialysis patients, it is important to maintain serum Ca, P,
and iPTH within the appropriate ranges. For this, serum Ca and
P should be measured monthly or more frequently (depending
on the clinical settings). The measurement of iPTH should be
conducted at least once every 3 months.
Control of hyperphosphatemia and maintenance of serum
Ca, P, and iPTH levels within the target ranges in CKD patients
are the mainstay of the management of CKD-MBD. Thus,
biochemical tests for Ca, P, and iPTH must be performed
regularly, and it is recommended to measure patients’ serum
Ca and P at least once per month. The measurement interval ofTable 1. Target levels of serum phosphorus, calcium, and parathyroid h
Phosphorus (mg/dL) Calc
KDIGO [7] Towards normal range Toward
ERBP [11] 2.4–4.5 Toward
UKRA [10] 2.78–4.64
CARI [8] 4.95
KDOQI [6] 3.5–5.5
JSDT [9] 3.5–6.0
CARI, Caring for Australians with Renal Impairment; ERBP, European Renal B
Disease: Improving Global Outcomes; KDOQI, Kidney Disease Outcome QuaiPTH is 3–6 months by the KDIGO guidelines, and is 3 months
according to the KDOQI and JSDT guidelines. Considering these
three guidelines and our NHIS, we recommend that the iPTH
level should be measured once every 3 months. However,
laboratory tests may be performed more frequently based on
clinical decisions until the test results are optimalized. In
particular, biochemical tests should be performed more fre-
quently during active suppression of secondary hyperparathyr-
oidism using vitamin D receptor activators (VDRAs) or
calcimimetics. Even when the value of each biochemical test
result falls within the target range, it is important to identify a
trend of change. If the iPTH levels are increased, serum
alkaline phosphatase may also be measured, as necessary. In
cases of decreased serum Ca level, the serum albumin con-
centration should also be measured to obtain the corrected Ca
because only the total, but not ionized (biologically active),
serum Ca concentration may be lowered by hypoalbuminemia.
The corrected Ca concentrations can be calculated by two
different formulae recommended by the KDIGO and JSDT
guidelines.
KDIGO method [7]:
Corrected total Ca (mg/dL) ¼ measured Ca (mg/dL)
þ 0.8  [4 – serum albumin (g/dL)].
JSDT method [9]:
Corrected total Ca (mg/dL) ¼ measured Ca (mg/dL)
þ [4 – serum albumin (g/dL)].
Table 2 summarizes our recommendation on the frequency
of serum mineral measurements and their target ranges. In the
latter part of this article, we will describe in detail the target
ranges of serum Ca, P, and iPTH.
Consideration of dialysate Ca concentration
Although dialysate Ca concentrations may be individualized
for successful HD, the KDIGO [7], ERBP [11], and JSDT [9]
guidelines recommend that the dialysate Ca concentration be
maintained between 2.5 mEq/L and 3.0 mEq/L (1.25–1.5mM).
Serum Ca levels usually change in parallel with dialysate Caormone presented by different guidelines
ium (mg/dL) Intact parathyroid hormone (pg/mL)
s normal range 2–9  normal range
s normal range 100–800
8.8–10.0 Not mentioned
8.5–10.5 100–470
8.4–9.5 150–300
8.4–10.0 60–240
est Practice; JSDT, Japanese Society for Dialysis Therapy; KDIGO, Kidney
lity Initiative; UKRA, United Kingdom Renal Association.
Table 3. Phosphorus and protein content of selected foods
Food Common
measure
(g)
Phosphorus
content
(mg)
Protein
content
(g)
Phosphorus
(mg) / protein
(g) ratio
Chicken, leg,
meat only,
fried or ﬁred
60 115.8 17.0 4.1
Chicken, breast,
meat only,
fried
60 148.8 20.0 4.5
Kidney Res Clin Pract 34 (2015) 4–126concentrations. Thus, a dialysate Ca concentration at 2.5 mEq/L
lowers the serum Ca level, enabling the liberal use of VDRAs or
Ca-containing phosphate binders. However, low dialysate Ca
concentrations may provoke hypotension during HD [12–14].
In case of using cinacalcet, a higher dialysate Ca concentration
may be advantageous to avoid hypocalcemia. Here, we recom-
mend that the dialysate Ca concentration should be properly
determined within the range of 2.5–3.0 mEq/L (1.25–1.5mM),
considering the individual dietary intake of Ca and use of
phosphate binders, VDRAs, and cinacalcet.Pork, ribs,
roasted
60 135.6 14.0 5.8
Pork, belly 60 79.2 10.3 4.6
Beef, Korean
cattle, loin
60 99.0 12.6 4.7
Beef, imported
cattle, brisket,
braised
60 112.2 14.0 4.8
Mackerel,
broiled
60 144.0 14.5 6.0
Spanish
mackerel,
broiled
60 156.0 14.2 6.6
Chum salmon,
smoked
60 141.0 13.8 6.1
Chicken's egg,
broiled
60 123.6 7.3 10.2
Soybean curd,
pressed
80 72.0 6.7 8.6
Potatoes,
steamed
100 35.0 1.9 18.4
Sweet potatoes,
steamed
100 40.0 1.1 36.4
Chestnuts, raw 60 40.8 1.9 12.8
Peanuts, dried 10 39.8 2.5 1.6
Milk, ordinary
liquid milk
200 178.0 6.4 55.6
Yogurt, liquid
type
150 93.0 2.3 62.0
Adapted with permission from the Nutritious Food Table, 8th Revision,
2011, National Academy of Agricultural Science.Dietary P restriction
In adult dialysis patients with serum P 4 4.5 mg/dL, the
daily dietary P intake should be limited to o 800 mg. To
achieve the goal of limiting P intake while maintaining the
protein intake, it is recommended that patients select diets
with a low phosphorus–protein (P-P) ratio. Thus, P additives
found in some carbonated beverages and processed meat
should be avoided.
The current HD procedures and phosphate binders offer
only limited effects of P removal, and it is necessary to restrict
the dietary intake of P. The daily P intake of a healthy person is
known to be approximately 1,000–2,000 mg [15], and it needs
to be restricted to approximately 800 mg in adult dialysis
patients [16]. An observational study reported that a higher
dietary P intake and a higher dietary P-P ratio were associated
with an increased mortality [17]. Consequently, dietary P
intake restriction should be enforced for dialysis patients with
serum P concentrations 4 4.5 mg/dL.
Organic P, which is ingested from food, can be categorized
into vegetable and animal P, whereas inorganic P exists as an
additive in processed foods [18]. P contained in vegetable-based
foods, such as nuts, exhibits a low gastrointestinal absorption
rate (bioavailability, 20–40%), while P contained in animal-
based foods, such as yogurt, demonstrates a high gastrointest-
inal absorption rate (bioavailability, 40–60%). In particular,
the bioavailability of inorganic P included as an additive and
preservative in carbonated beverages reaches 80–100%. Thus,
for the control of serum P concentrations, it is necessary to limit
the intake of inorganic P and natural P contained in foods rich in
animal protein. However, as the protein intake is also related to
patient survival, it should be noted that the daily protein intake
needs to be at least 1.1 g/kg [19]. If the serum P concentration is
o 2.4 mg/dL, the nutritional status of the patient should be re-
evaluated, and the dietary intake of P and protein should be
encouraged.
In general, the dietary P content is proportional to protein
intake, as shown in the equation below [20].
Dietary P ðmgÞ ¼ 78þ11:8 protein intake ðgÞ
Thus, it is possible that restrictions on the dietary P intake
can, in turn, lead to protein deﬁciency, as limiting dietary P
intake is accompanied by a decrease in protein intake [21].
Furthermore, a previous study showed that dietary prescrip-
tions of limited P intake did not increase the survival rate of
dialysis patients [22]. It is not clear whether dietary treatments
actually produce long-term beneﬁts in improving hyperpho-
sphatemia [23].
As shown in Table 3, there are large differences in the P-P
ratio, depending on the food sources. Hence, if food with a low
P-P ratio is selected, the goal of dietary P intake restriction maybe achieved with maintaining protein intake. Because it is
important to avoid the P additives included in carbonated
beverages and processed meats, patients must avoid fast foods.
In cases of cooking foods with a high P content, boiling the
food is helpful for lowering its P content [16].Treatment of hyperphosphatemia
We suggest that serum P concentration be maintained
within the target range of 2.4–5.0 mg/dL. In addition to
adequate dialysis, the administration of phosphate binders is
usually required to control hyperphosphatemia. The status of
serum Ca and iPTH should be considered when selecting a
phosphate binder.
It is well known that hyperphosphatemia in CKD patients
stimulates PTH secretion from the parathyroid glands and
induces soft tissue and vascular calciﬁcation [24,25]. In parti-
cular, the increased incidence of CVD in CKD patients has been
known to be associated with abnormal Ca-P metabolism [26].
Consequently, maintaining the serum P level within the
Hwang et al / Management of CKD-MBD 7normal range is vital for managing complications in these
patients.
The target ranges of the serum P level differ modestly
between the different guidelines. Determining the target
range of the serum P was mainly based on the previous
observational studies. Block et al [27] retrospectively stu-
died 40,000 HD patients and reported that the relative risk
of mortality was the lowest in patients who maintained
their serum P concentrations within 3.5–5.5 mg/dL. Conse-
quently, the KDOQI guideline set the target range at 3.5–
5.5 mg/dL [6]. In 2009, the KDIGO guidelines recommended
that serum P level be more strictly controlled by maintain-
ing it within the normal range because of the lack of well-
performed randomized controlled trials [7]. By contrast, a
study from Japan reported that there was no difference in
the mortality between patients who maintained serum P
level within 3.6–5.0 mg/dL and those who maintained it
within 4.1–6.0 mg/dL or 4.1–5.5 mg/dL [28]. As a result, the
JSDT guidelines recommended that serum P level be main-
tained at 3.5–6.0 mg/dL [9]. In Korea, no longitudinal studies
on the association between mortality risk and serum P
concentration have been reported. According to a recent
study by Kim et al [5], the average serum P concentration of
dialysis patients was 5.3 mg/dL. In total, 51% of the patients
were maintaining serum P concentration within the KDOQI
target range of 3.5–5.5 mg/dL. Furthermore, 40.7% of the
patients had their serum P level 4 5.5 mg/dL, indicating
that serum P concentration is not properly controlled in a
substantial number of Korean dialysis patients [5]. Although
the supporting evidence is not strong in this country, we
recommend that a phosphate binder be administered when
serum P concentration is 4 5.0 mg/dL.P removal through dialysis
Although HD has advanced signiﬁcantly with the devel-
opment of dialysis membranes and the use of ultrapure
dialysate, there are limitations in terms of P removal
through dialysis. The kinetics of P differs from those of other
low molecular weight substances. Most P exists in the bones
or teeth, and only 1% exists in the blood. As a result, the
amount of P removed from the body through dialysis is
extremely limited.
The amount of P removed by conventional HD (3 times/wk,
4 h/session) is approximately 2.3–2.6 g/wk, and the amount
removed by PD (4 times/d, 2-L exchanges) is 2.0–2.2 g per
week. If the session length of HD is extended to 5 hours or
more, the removal of P increases to 3.0–3.6 g/wk. If nocturnal
HD (8 hours/day) is performed, the removal of P can increase
to 4.5–4.9 g, which corresponds to twice of that removed by
conventional HD [29]. However, the amount of P removed
through postdilution hemodiaﬁltration is 3.0–3.3 g, which is
only a small increase compared to conventional HD [16].
Currently, the majority of patients receive conventional dia-
lysis, and only a very small number of patients undergo
nocturnal HD or hemodiaﬁltration in Korea. Thus, if the daily
dietary P intake is assumed to be 800 mg, the amount of P
removed through weekly conventional dialysis is only half of
the dietary intake. Thus, the administration of phosphate
binders would be inevitable for controlling the serum P
concentration in our dialysis patients.Use of phosphate binders
The currently available phosphate binders are aluminum-
containing phosphate binders, Ca-containing phosphate binders,
and non Ca-based phosphate binders. The advantages of
aluminum-containing phosphate binders (e.g., aluminum hydro-
xide) are their excellent phosphate binding capacity and low cost,
whereas the drawback is the risk of aluminum accumulation in
the body. Due to the risks of aluminum-induced osteomalacia and
encephalopathy, the long-term use of aluminum hydroxide is no
longer recommended [30].
Ca-containing phosphate binders, either Ca carbonate or Ca
acetate, began to be actively used in clinical practice in the 1980s.
Although Ca-containing phosphate binders have slightly lower
phosphate-binding capacity than aluminum-containing phosphate
binders, they are cost-effective and have no risk of aluminum
accumulation. However, increased Ca loading and the Ca-P
product are linked to hypercalcemia and vascular calciﬁcation.
In addition, excessive inhibition of iPTH release and development
of adynamic bone disease may ensue.
In a recent observational study, the mortality rate was 19%
lower in patients using phosphate binders compared to those
who did not [31]. However, when the data were adjusted for sex,
age, and morbidity, no signiﬁcant difference in the mortality
rate was found between the groups. As such, the relationship
between Ca-containing phosphate binders and mortality must
be clariﬁed through additional studies.
With respect to non Ca-based phosphate-binders, sevela-
mer hydrochloride/carbonate and lanthanum carbonate are
used in this country. Sevelamer has the advantage of reducing
Ca overload, owing to its lack of Ca content as an anion-
exchange resin, but has drawbacks of its relatively low phos-
phate binding capacity and high price. Moreover, sevelamer is
known to have additional advantages of decreasing serum
cholesterol and uric acid concentration, and it has anti-
inﬂammatory effects. Block et al [32] studied 129 incident
HD patients in whom either Ca-containing phosphate binders
or sevelamer was administered for 18 months. They found that
coronary artery calciﬁcation advanced more quickly in patients
taking Ca-containing phosphate-binders compared with those
receiving sevelamer. Furthermore, when the same patients
were monitored through follow-ups for the next 44 months,
patients who had been administered sevelamer exhibited a
lower mortality rate [33]. By contrast, sevelamer administra-
tion did not exhibit a signiﬁcant difference in mortality
compared to Ca-containing phosphate binders in another
study involving 2,103 patients [34].
Lanthanum carbonate, a non-Ca-, nonaluminum-containing
phosphate binder, is a trivalent metal and is minimally absorbed
by gastrointestinal tract. Its phosphate-binding capacity is known
to be identical or superior to that of aluminum-containing
phosphate binders. However, any potential side effects associated
with accumulation within the body are currently unknown.
A previous study, in which lanthanum carbonate and
another phosphate binder were randomly assigned to approxi-
mately 1,300 HD patients and followed for 2 years, showed
that lanthanum had superior medication adherence and efﬁ-
cacy [35]. In PD patients, the serum P level was effectively
controlled through high-dosage administration (2,250 mg/
day) of lanthanum carbonate [36]. Furthermore, a recent study
reported that treatment with lanthanum was independently
associated with a signiﬁcant survival beneﬁt in HD patients
with inadequately controlled hyperphosphatemia [37]. Despite
Table 4. Equivalent dosage for dialysis patients switching from
calcium acetate to sevelamer or lanthanum
Calcium
acetate
667 mg
Sevelamer
hydrochloride
400 mg
Sevelamer
hydrochloride
800 mg
Lanthanum
carbonate
500 mg
1 tablet 2 tablets 1 tablet 0.5 tablets
2 tablets 3 tablets 2 tablets 1 tablet
3 tablets 5 tablets 3 tablets 1.5 tablets
Adapted with permission from: Daugirdas JT, Finn WF, Emmett M,
Chertow GM; Frequent Hemodialysis Network Trial Group: The phos-
phate binder equivalent dose. Semin Dial 24: 41–49, 2011.
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of potential side effects induced by long-term use of lantha-
num. In particular, the development of bone toxicity due
to lanthanum accumulation should be closely monitored in
patients with long-term lanthanum use. Table 4 shows the
equivalent dosage information for cases in which a Ca-
containing phosphate binder is switched into a non–Ca-based
phosphate binder [38].Treatment of secondary hyperparathyroidism
We suggest that in CKD stage 5D, serum iPTH levels be
maintained within the range of 100–300 pg/mL. To achieve
this target range, dialysis patients can be medicated when the
iPTH is elevated 4 200–300 pg/mL. If the iPTH level is o
150 pg/mL, medications should be reduced. In dialysis patients
with an iPTH level o 100 pg/mL, efforts to avoid adynamic
bone disease are necessary. Parathyroidectomy is indicated
when the iPTH level is persistently 4 500 pg/mL, despite
appropriate medical treatment.
According to the 2014 Korean NHIS for treating secondary
hyperparathyroidism (SHPT), administration of calcitriol is
indicated when iPTH is elevated 4 200 pg/mL. The KDIGO
guidelines recommended that the iPTH level be 2–9 times the
normal range (i.e., 130–585 pg/mL, given the upper normal
value of 65 pg/mL) [7,11]. By contrast, the target ranges of iPTH
are 150–300 and 60–240 pg/mL, according to the KDOQI, and
JSDT guidelines, respectively [6,9]. Considering that many
Korean HD patients were in the low range of iPTH [5] and
that the best survival rate was achieved in Japanese HD
patients whose iPTH was approximately 180 pg/mL [28], we
believe that the iPTH levels within 100–300 pg/mL would be
appropriate in this country. However, the Evaluation of Cina-
calcet Hydrochloride Therapy to Lower Cardiovascular Events
(EVOLVE) trial failed to demonstrate that effective suppression
of iPTH could reduce the risk of death or major cardiovascular
events in dialysis patients [39]. Therefore, we currently suggest
that the upper allowable limit of iPTH be 500 pg/mL.
The Korean NHIS approves the use of paricalcitol and cinacalcet
when iPTH is 4 300 pg/mL. However, they ask us to choose
calcitriol as the ﬁrst line drug before prescribing paricalcitol or
cinacalcet. We believe that the choice of VDRA should be at the
discretion of physicians, and should consider the prior treatment
history and current conditions of each patient. The latter include
states of serum minerals, bones, and extraskeletal organs. Treat-
ment may be necessary even if the iPTH level does not exceed
300 pg/mL. If the serum Ca exceeds 11mg/dL, for instance,
parathyroid function is partially inhibited and iPTHwill not exceed300 pg/mL. However, hyperparathyroidism treatment is still
necessary for the correction of the mineral imbalance. Thus, the
current Korean NHIS for restricting treatment should be revised
because they serve only to delay surgery and result in cyclic
improvements and deteriorations of hyperparathyroidism. By
contrast, the ongoing treatment should be reduced if the iPTH
level decreases to o 150 pg/mL. A further decrease of iPTH level
o 100 pg/mL implies adynamic bone disease and a possibility of
extraskeletal calciﬁcation, and treatment to suppress iPTH should
be stopped. In cases of iPTH 4 500 pg/mL, surgical treatment
should be considered if appropriate medical treatment is not
successful.Medical treatment
To prevent SHPT, the control of hyperphosphatemia is impor-
tant using dietary restriction, adequate dialysis, and reasonable
phosphate binders. To suppress the excessive parathyroid hor-
mone release, VDRAs (calcitriol, paricalcitol) and/or calcimimetics
are useful according to the patient conditions. Surgical treatment
should only be indicated for SHPT that cannot be controlled by all
efforts with medical treatment.
VDRAs
In predialysis patients, oral calcitriol can be administered if
the patient has hypocalcemia or elevated iPTH levels. Intrave-
nous calcitriol (0.5–1.5 μg 1–3 times/wk) can be used for
dialysis patients whose iPTH is 4 200 pg/mL. Paricalcitol can
be administered if iPTH is 4 300 pg/mL. When VDRAs are
administered, their dosage should be adjusted by measuring
serum Ca, P, and iPTH levels every 2–4 weeks.
VDRAs are clinically useful as they act on parathyroid by a
feedback mechanism. According to the 2014 Korean NHIS, oral
calcitriol is allowed in patients with estimated glomerular
ﬁltration rate o 40 mL/min/1.73 m2. The appropriate weekly
dosage is 0.5–1.5 μg. The recommended iPTH levels in the
2003 KDOQI guidelines were o 70 pg/mL in CKD stage 3 and
o 110 pg/mL in CKD stage 4 [6]. Furthermore, according to the
2014 Korean NHIS, intravenous calcitriol can be administered
if the iPTH level is 4 200 pg/mL and the PTH-lowering
responses are refractory to oral calcitriol. The typical dosage
per dialysis is 0.5–1.5 μg, with the maximum dose being 5 μg.
However, because calcitriol increases gastrointestinal absorp-
tion of Ca and P and causes increases in the serum Ca and P
levels and vascular calciﬁcation, more speciﬁc drugs targeting
the parathyroid gland are under development. Among these
new drugs, the third-generation drug paricalcitol is currently
used in Korea.
Paricalcitol has the advantage of inducing less hypercalce-
mia in patients with SHPT, and has been shown to decrease the
cardiovascular morbidity and mortality in an observational
study [40]. In patients with iPTH levels 4 300 pg/mL,
a smaller initial dose of paricalcitol is chosen between iPTH/
120 and 0.04–0.1 μg/kg. The dose may be adjusted at 2–4 week
intervals, based on relationship between subsequent iPTH
levels and baseline iPTH level, up to 0.24 μg/kg per dialysis.
When the dosage is increased until an initial response is
observed, it is recommended that the levels of Ca and P be
measured at least once every 2 weeks (up to twice a week).
When the iPTH levels reach the target range, the dose of
paricalcitol can gradually be reduced. The initial dose of
Hwang et al / Management of CKD-MBD 9paricalcitol is usually 2–5 μg per dialysis, and the dosage
during maintenance can gradually be decreased by 1–2 mg
per dialysis (1/3 or 1/4 of dosage), while the iPTH and mineral
levels are monitored [6]. If the iPTH level is o 150 μg/mL, the
administration should be reduced or halted. If the iPTH level is
o 100 pg/mL, discontinuation of VDRAs should be considered.
After halting the treatment, if iPTH increases to 4 100 pg/mL,
the drug can be re-administered with a half of dosage used
before the treatment was halted. If the drug was already
administered at a minimum dosage prior to halting the
treatment, the intervals of drug administration can be adjusted
to once every two administrations [6]. If the drug administra-
tion is halted at iPTH o 300 pg/mL according to the 2014
Korean NHIS, the iPTH level will rebound, necessitating a
higher dosage during re-administration. The resultant ﬂuctua-
tions of iPTH may lead to progressive hyperparathyroidism,
and we believe the drug maintenance guidelines by the Korean
NHIS should be revised.Cinacalcet
Cinacalcet can be administered if the iPTH level is 4
300 pg/mL. The initial dosage is 25 mg and should be admi-
nistered during dinner. When cinacalcet is administered or its
dosage is changed, serum Ca measurement should be consid-
ered at the next dialysis session. In addition, P and iPTH should
be measured every 3 or 4 weeks to adjust the dosage.
Calcimimetics decrease PTH by transmitting signals into the
cells from parathyroid Ca sensing receptors. As Ca sensing
receptors exist not only in the parathyroid, but also in the
vessels and other organs, calcimimetics are predicted to play a
protective role in the cardiovascular system. Calcimimetics are
particularly useful in patients with SHPT with increased Ca and P
levels. The bioavailability of cinacalcet is low (20–25%), and the
ﬁrst-pass effect of cinacalcet in the liver is large. Thus, it is
recommended to be taken with food, as this increases its
bioavailability by 1.5–1.8 times [41]. As the peak blood concen-
tration is reached 2–6 hours after drug administration, its effect
can be properly evaluated by the blood test conducted in the
following morning if the drug is taken during dinner [41]. The
recommended drug dosage is from 25 mg and can be increased
by 25mg every 3 or 4 weeks, up to 100 mg. Typical adverse
events include hypocalcemia and gastrointestinal symptoms
(nausea, vomiting, diarrhea, etc.). Thus, monitoring of hypocal-
cemia is necessary while cinacalcet is administered. The mon-
itoring intervals are determined based on the serum Ca level of
the patients. The Ca level should be measured immediately
before the next dialysis session. According to the 2014 Korean
NHIS, cinacalcet is initially indicated when iPTH is 4 300 pg/mL
and serum Ca is 4 9.0 mg/dL. The dosage can be increased if Ca
is 4 8.4 mg/dL. It can be maintained without being increased
when the Ca level is 4 7.5 mg/dL, but it should not be
administered when the Ca level is o 7.5 mg/dL.
Calcimimetics can be used alone or administered combined
with VDRAs, including calcitriol, when necessary. Similar to
paricalcitol, the administration of calcimimetics is recom-
mended to be stopped if iPTH is o 300 pg/mL according to
the 2014 Korean NHIS. This strategy will lead to the iPTH
rebound, consequently requiring a greater dosage of calcimi-
metics. Thus, the Korean NHIS regarding drug maintenance
should be revised to decrease the risks of parathyroidectomy,
cardiovascular complications, and bone disorders due to SHPT.Selection of VDRAs and/or cinacalcet, based on the serum Ca
levels
Calcitriol should be considered ﬁrst if the serum Ca is
o 8.4 mg/dL. If the serum Ca is 8.4–9.0 mg/dL, calcitriol or
paricalcitol can be administered depending on the serum P
level. If the serum Ca is 9.0–10.2 mg/dL, paricalcitol and
cinacalcet are preferred. Depending on the serum Ca and P
levels, the drugs should be taken alone or as combination
therapy. If the serum Ca is 4 10.2 mg/dL, cinacalcet should be
primarily considered. Paricalcitol may also be considered as a
part of combination therapy depending on the serum Ca and P
levels.
Serum Ca o 8.4 mg/dL
In this situation, correcting hypocalcemia should be a
priority because the increase in PTH is a physiological com-
pensatory phenomenon. Calcitriol is the primary treatment
option at daily doses of 0.25-0.5 μg depending on the serum Ca
concentration. For treatment of hypocalcemia, daily oral
administration is better than pulse intermittent therapy. After
the serum Ca level is normalized, the iPTH level should be
followed for re-evaluation. If the serum P is 4 5.0 mg/dL, a
phosphate binder should be combined.
Serum Ca 8.4–9.0 mg/dL
Either calcitriol or paricalcitol can be used. We suggest
calcitriol and paricalcitol in patients with serum P o 5.0 and
Z 5.0 mg/dL, respectively. In both cases, appropriate phos-
phate binders may be added. The Korean NHIS demands that
oral calcitriol should be the ﬁrst choice of hyperparathyroid-
ism treatment in the patients with iPTH 4 200 pg/mL, and
that intravenous calcitriol can be administered when the oral
administration is ineffective because of the cost difference.
Although the efﬁcacy is not affected by the route of adminis-
tration, the drug compliance may be enhanced by intravenous
use. However, the intermittent pulse dosage, for instance,
three times a week, is more advantageous than the daily
administration of calcitriol because of less hypercalcemia and
hyperphosphatemia. Although a dosage of up to 5 μg is
possible during dialysis, the practical oral and intravenous
doses of calcitriol are 0.25–0.75 mg and 0.5–1.0 mg, respec-
tively, due to the risk of hypercalcemia and hyperphosphate-
mia [6]. If the iPTH level is persistently 4 300 pg/mL despite
the use of calcitriol, paricalcitol would be the alternative.
Paricalcitol may also be superior to calcitriol in patients with
overt hyperphosphatemia.
Serum Ca 9.0–10.2 mg/dL
Paricalcitol and cinacalcet are preferred to calcitriol because
of the risk of hypercalcemia and vascular calciﬁcation. When
the serum P level is o 2.4 mg/dL, paricalcitol is the best option
because cinacalcet may further reduce the serum P. Depending
on the serum Ca and P levels, paricalcitol and cinacalcet can be
administered alone or as combination therapy.
Serum Ca 4 10.2 mg/dL
Cinacalcet is preferred to pericalcitol. In patients with the
serum P o 2.4 mg/dL, however, cinacalcet may not be useful
because it can further reduce the serum P level. Depending on
the serum Ca and P levels, paricalcitol and cinacalcet can be
administered alone or as combination therapy.
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Parathyroidectomy should be considered if the following
three ﬁndings persist despite appropriate medical treatments:
(1) iPTH 4 500 pg/mL; (2) parathyroid 4 500 mm3 in size
upon ultrasonography; and (3) uncontrollable hypercalcemia
and hyperphosphatemia, X-ray ﬁndings of a bone disorder,
severe bone and muscle pain, calciphylaxis, or soft tissue
calciﬁcation. Preoperative parathyroid imaging to localize the
lesion is necessary. The surgical method should be determined
based on the overall status of the patient, the future plan of
kidney transplantation, and the presence of thyroid pathology.
SHPT that cannot be managed by medical treatment
requires surgical treatment. Although ethanol or calcitriol
can be injected into the parathyroid gland for ablation, the
high risk of recurrence and a possibility of adhesion are
anticipated. Hence, surgery is preferred as long as an experi-
enced surgeon is available. Future plans of kidney transplanta-
tion and cardiovascular status of the patient will determine
the methods of surgery and anesthesia. Although subtotal
parathyroidectomy and total parathyroidectomy with auto-
transplantation are the representative surgical methods, lim-
ited parathyroidectomy, single parathyroidectomy, or total
parathyroidectomy without autotransplantation can also be
performed, depending on the situations [42]. In exceptional
cases, parathyroidectomy may be performed through local
anesthesia if the patient is at a high risk for general
anesthesia-related complications. The localization of parathyr-
oid glands is important in preoperative evaluation. Parathyroid
imaging methods include sestamibi parathyroid scans, neck
ultrasound, and neck computed tomography scans.
The speciﬁc ﬁndings of medical treatment failure, indicative
of parathyroidectomy, include the following: (1) iPTH 4
500 pg/mL; (2) parathyroid 4 500 mm3 in size, as determined
by ultrasonography; and (3) unmanageable hypercalcemia andFigure 1. Summary of the treatment strategy for control of secondary
phosphorus.
1NCPB, non–calcium-based phosphate binder, is reimbursed for P Z 5.5 mg
Insurance Standards, as of July 2014).hyperphosphatemia, X-ray ﬁndings of a bone disorder, severe
bone and muscle pain, calciphylaxis, or soft tissue calciﬁcation.
If all these three ﬁndings are present after all avenues of
medical treatment, surgical treatment should be applied [43].
Because the major postoperative complication is hypocal-
cemia, serum Ca levels should be monitored every 4–6 hours
for 48–72 hours after surgery. Subsequently, the serum Ca
level should be measured twice daily. If the ionized Ca is o
3.6 mg/dL and the corrected total Ca is o 7.2 mg/dL, 10 mL of
10% Ca gluconate containing 90 mg of Ca should be adminis-
tered at a rate of 1–2 mg/kg/h. Eventually, the ionized Ca
should be maintained within a range of 4.6–5.4 mg/dL [6].
Phosphate binders, if used, should be replaced by calcium
carbonate 1–2 g three times (between meals) a day for the
purpose of Ca supplementation. Calcitriol should be adminis-
tered in addition to intravenous Ca until the serum Ca reaches
the target range. When oral administration of Ca is possible,
the patient can be treated as an outpatient. Recurrence is
possible if kidney transplantation is not undertaken, and close
monitoring is recommended.Conclusion
Abnormal Ca and P metabolism leading to the development
of SHPT and cardiovascular calciﬁcation can be complicated
during the early course of CKD, when glomerular ﬁltration rate
falls o 60 mL/min/1.73 m2. Thus, early interventions to cor-
rect abnormal Ca and P metabolism are important to reduce
cardiovascular morbidity and mortality. However, many dia-
lysis patients in Korea were reported to have out-of-range
levels for serum Ca, P, and iPTH. Because we do not have our
own practice guidelines for the management of CKD-MBD, we
may need to adapt the major international guidelines and
update the evidence-based medicine in this practice area.hyperparathyroidism according to the level of serum calcium and
/dL, and Ca-P Z 55 mg2/dL2 (according to the Korean National Health
Hwang et al / Management of CKD-MBD 11Additionally, we should follow the guidance of the Korean
NHIS. Considering these current situations, Fig. 1 summarizes
our recommendation for the optimal treatment of abnormal
serum Ca and P and SHPT. Large-scale, well-designed clinical
studies are required to support our strategies to control CKD-
MBD in Korea. Based on such data, our practice guidelines
could be developed and better long-term outcomes should be
anticipated in our dialysis patients.Conﬂict of interest
The authors have served on an advisory panel for AbbVie
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